NGDC - GSA for Human

HRA014751

HRA014751.xlsx

Title:

Targeting TPX2-dependent lineage plasticity in neuroendocrine bladder carcinoma with CDK4/6 inhibition

Release date:

2026-02-16

Description:

Neuroendocrine bladder carcinoma (NEBC) is an aggressive and therapy-resistant cancer with poor prognosis. Through integrated transcriptomic analysis, we identified a lineage plasticity-associated signature and subsequently characterized a subpopulation of bladder cancer cells with high TPX2 expression at the single-cell level, which lack canonical neuroendocrine markers but are associated with adverse clinical outcomes.Functional studies showed that TPX2 promotes lineage plasticity and induces T cell exhaustion. Notably, palbociclib, a selective CDK4/6 inhibitor that effectively targeted cell cycle dysregulation, demonstrated potent antitumor effects in preclinical models of both TPX2high and NEBC patients. These findings highlight TPX2high cells as a transitional state in disease progression and suggest that combining CDK4/6 inhibitors with immune checkpoint blockade may improve therapeutic efficacy in NEBC and TPX2high patients.

Data Accessibility:

Controlled access Request Data

BioProject:

PRJCA045707

Study type:

Disease Study

Disease name:

urinary bladder cancer

Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.

DAC NO.:

HDAC006722

DAC name:

DAC of Department of Urology

Contact person:

Chen Xu

Email:

chenx457@mail.sysu.edu.cn

Description:

DAC of department of urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Aspera Command Line